Key Drivers
- Margin strength
- Dividend risk
- Intangible heavy
AIAI Summary
QGEN still has strong margins and credible launch momentum, but the recent guidance cut and softness in QuantiFERON/U.S. life sciences shift the stock from a clean compounder to a hold-and-watch name where upside now depends on product adoption and demand normalization rather than multiple expansion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Dividend risk
- •Intangible heavy
QGEN is fundamentally solid with strong margins, liquidity, and cash flow, but recent profitability softened and the dividend looks stretched.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance test
- •Stretched rally
QGEN is in a constructive last month uptrend, but after rallying to $40.10 it is stretched near key resistance and should be watched for either a clean breakout or a pullback toward $39.1–$39.4 support.
Fast climb from $36.28 to $40.10 over the last month raises short-term pullback risk
Sentiment & News
Key News Insights:
- •Share Strength
- •dPCR Expansion
- •Broader Use Cases
QIAGEN's shares remain strong while the company deepens its digital PCR push with new assays and workflow tools, reinforcing broader platform adoption and investor attention.
The news is modestly positive for QGEN, supporting near-term momentum as product expansion broadens the platform's growth potential
Similar Companies in Healthcare
Other companies in the same sector with AI ratings